USANA Health Sciences Amends $75 Million Revolving Credit Facility With Bank of America; Matures 2030
USANA Health Sciences amended its $75 million revolving credit facility with Bank of America, extendable to $200 million, maturing in 2030. The amendment adds EBITDA covenants, increases asset sale limits, and adjusts sale-leaseback restrictions. Management aims to enhance liquidity and flexibility.
How this was made
The 30-second read
Why it matters
The amendment provides additional flexibility but introduces tighter financial covenants, likely resulting in a neutral short‑term price reaction.
Market read
A modest corporate credit amendment with limited immediate trading impact; relevant mainly for USNA shareholders and credit‑focused investors.
What to watch
Potential future drawdown of the facility up to $200 M could increase leverage if the company taps the full amount.
Background
USANA Health Sciences is a nutrition and supplement company that maintains a revolving credit facility for working capital and acquisitions.
Ticker impact
USANA Health Sciences filed an 8‑K announcing a first amendment to its $75 million revolving credit facility, adding new EBITDA covenants and extending maturity to 2030.
likely limited pressure as the market prices in the modest credit enhancement.
Credit facility amendments are routine corporate actions; the modest $75 M size and new covenant constraints do not suggest a strong directional move.
Market effects
May signal tighter credit standards for health‑supplement firms, but impact is limited to USNA.
No broader regional effect; the amendment is company‑specific.
Minimal global relevance; only affects USNA investors.
Counterpoint
If the new EBITDA covenant proves restrictive, the stock could face downside pressure if earnings miss the higher threshold.
Key entities
- Administrative AgentBank of America
Serves as the administrative agent for the revolving credit facility.
